Please see FAQ for latest information on COVID-19 Data Hub Data Flows https://covid-19.geohive.ie/pages/helpfaqs
Category
Field Label
Field Display Name
Explanation
ExtractDate
ExtractDate
Date the data is extracted
Latitude
Latitude
Longitude
Longitude
EpiWeek
EpiWeek
Details of epidemiological weeks available here https://www.hpsc.ie/notifiablediseases/resources/epidemiologicalweeks/
Week
Week
Details of epidemiological weeks available here https://www.hpsc.ie/notifiablediseases/resources/epidemiologicalweeks/
WeeklyBoosterVaccines
Weekly Booster Vaccines
Amount of boosters given during week
Vaccine Brand
AstraZeneca
AstraZeneca
Janssen
Janssen
Moderna
Moderna
Pfizer
Pfizer
Additional Doses by Brand
AD_AstraZeneca
AdditionalDoses AstraZeneca
AD_Janssen
AdditionalDoses Janssen
AD_Moderna
AdditionalDoses Moderna
AD_Pfizer
AdditionalDoses Pfizer
Immunocompromised Doses by Brand
ID_AstraZeneca
ImmunocompromisedDoses AstraZeneca
ID_Janssen
ImmunocompromisedDoses Janssen
ID_Moderna
ImmunocompromisedDoses Moderna
ID_Pfizer
ImmunocompromisedDoses Pfizer
Gender
Male
Male
Female
Female
Not Assigned
NA
Age Group Additional Dose
AD_Age0to9
AdditionalDose Age5to11
Additional Dose Age 5 to 11
AD_Age10to19
AdditionalDose Age12to19
Additional Dose Age 12 to 19
AD_Age20to29
AdditionalDose Age20to29
Additional Dose Age 20 to 29
AD_Age30to39
AdditionalDose Age30to39
Additional Dose Age 30 to 39
AD_Age40to49
AdditionalDose Age40to49
Additional Dose Age 40 to 49
AD_Age50to59
AdditionalDose Age50to59
Additional Dose Age 50 to 59
AD_Age60to69
AdditionalDose Age60to69
Additional Dose Age 60 to 69
AD_Age70to79
AdditionalDose Age70to79
Additional Dose Age 70 to 79
AD_Age80_
AdditionalDose Age80+
Additional Dose Age 80+
AD_NA
AdditionalDose NotAssigned
Additional Dose Not Assigned To Age Group
Age Group Additional Dose Cumulative
AD_Age0to9_Cum
AdditionalDose Cumulative Age5to11
Additional Dose Cumulative Age 5 to 11
AD_Age10to19_Cum
AdditionalDose Cumulative Age12to19
Additional Dose Cumulative Age 12 to 19
AD_Age20to29_Cum
AdditionalDose Cumulative Age20to29
Additional Dose Cumulative Age 20 to 29
AD_Age30to39_Cum
AdditionalDose Cumulative Age30to39
Additional Dose Cumulative Age 30 to 39
AD_Age40to49_Cum
AdditionalDose Cumulative Age40to49
Additional Dose Cumulative Age 40 to 49
AD_Age50to59_Cum
AdditionalDose Cumulative Age50to59
Additional Dose Cumulative Age 50 to 59
AD_Age60to69_Cum
AdditionalDose Cumulative Age60to69
Additional Dose Age 60 to 69
AD_Age70to79_Cum
AdditionalDose Cumulative Age70to79
Additional Dose Age 70 to 79
AD_Age80__Cum
AdditionalDose Cumulative Age80+
Additional Dose Cumulative Age 80+
AD_NA_Cum
AdditionalDose Cumulative Not Assigned
Additional Dose Cumulative Not Assigned To Age Group
Age Group Immunocompromised Dose
ID_Age0to9
ImmunocompromisedDoses Age5to11
Immunocompromised Dose Age 5 to 11
ID_Age10to19
ImmunocompromisedDoses Age12to19
Immunocompromised Dose Age 12 to 19
ID_Age20to29
ImmunocompromisedDoses Age20to29
Immunocompromised Dose Age 20 to 29
ID_Age30to39
ImmunocompromisedDoses Age30to39
Immunocompromised Dose Age 30 to 39
ID_Age40to49
ImmunocompromisedDoses Age40to49
Immunocompromised Dose Age 40 to 49
ID_Age50to59
ImmunocompromisedDoses Age50to59
Immunocompromised Dose Age 50 to 59
ID_Age60to69
ImmunocompromisedDoses Age60to69
Immunocompromised Dose Age 60 to 69
ID_Age70to79
ImmunocompromisedDoses Age70to79
Immunocompromised Dose Age 70 to 79
ID_Age80_
ImmunocompromisedDoses Age80+
Immunocompromised Dose Age 80+
ID_NA
ImmunocompromisedDoses Not Assigned
Immunocompromised Dose Not Assigned To Age Group
Age Group Immunocompromised Dose Cumulative
ID_Age0to9_Cum
ImmunocompromisedDoses Cumulative Age5to11
Immunocompromised Dose Cumulative Age 5 to 11
ID_Age10to19_Cum
ImmunocompromisedDoses Cumulative Age12to19
Immunocompromised Dose Cumulative Age 12 to 19
ID_Age20to29_Cum
ImmunocompromisedDoses Cumulative Age20to29
Immunocompromised Dose Cumulative Age 20 to 29
ID_Age30to39_Cum
ImmunocompromisedDoses Cumulative Age30to39
Immunocompromised Dose Cumulative Age 30 to 39
ID_Age40to49_Cum
ImmunocompromisedDoses Cumulative Age40to49
Immunocompromised Dose Cumulative Age 40 to 49
ID_Age50to59_Cum
ImmunocompromisedDoses Cumulative Age50to59
Immunocompromised Dose Cumulative Age 50 to 59
ID_Age60to69_Cum
ImmunocompromisedDoses Cumulative Age60to69
Immunocompromised Dose Age 60 to 69
ID_Age70to79_Cum
ImmunocompromisedDoses Cumulative Age70to79
Immunocompromised Dose Age 70 to 79
ID_Age80__Cum
ImmunocompromisedDoses Cumulative Age80+
Immunocompromised Dose Cumulative Age 80+
ID_NA_Cum
ImmunocompromisedDoses Cumulative NotAssigned
Immunocompromised Dose Cumulative Not Assigned To Age Group
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Each Age Group
BoosterPer_Age0to9
IDandADTotal % of Population Age5to11
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 5 to 11
BoosterPer_Age10to19
IDandADTotal % of Population Age12to19
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 12 to 19
BoosterPer_Age20to29
IDandADTotal % of Population Age20to30
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 20 to 29
BoosterPer_Age30to39
IDandADTotal % of Population Age30to40
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 30 to 39
BoosterPer_Age40to49
IDandADTotal % of Population Age40to50
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 40 to 49
BoosterPer_Age50to59
IDandADTotal % of Population Age50to60
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 50 to 59
BoosterPer_Age60to69
IDandADTotal % of Population Age60to70
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 60 to 69
BoosterPer_Age70to79
IDandADTotal % of Population Age70to80
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 70 to 79
BoosterPer_Age80_
IDandADTotal % of Population Age80+
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population In Age Group 80+
BoosterPer_NA
IDandADTotal % of Population Not Assigned
Immunocompromised Dose and Additional Dose Administered As A Percentage of Population Not Assigned To Age Group
Derilinx